This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication


Childhood cancer: Vulnerability in the immune response against metastases discovered

Credit: Unsplash/CC0 Public Domain

Scientists led by Sabine Taschner-Mandl, Ph.D., St. Anna Children's Cancer Research Institute, and Nikolaus Fortelny, Ph.D., Paris Lodron University of Salzburg, are the first to analyze bone marrow metastases from childhood tumors of the nervous system using modern single-cell sequencing analysis. It turns out that cancer cells prevent cells in their environment from fighting the tumor—a process that could be reversed with medication. The findings were published inNature Communications.

Neuroblastoma is the most common solid tumor in infants and young children. Despite constantly improving therapy options, more than half of the patients with a very aggressive form () still suffer from relapses. "We specifically studied bone marrow metastases because recurrences often originate there. The seem to manipulate their environment so that it supports their growth instead of fighting them," explains Sabine Taschner-Mandl, Head of the Tumor Biology Group at St. Anna Children's Cancer Research Institute (St. Anna CCRI).

How cancer cells manipulate their neighboring cells

The recently published study therefore examined the cell architecture and cell-cell communication of metastases of two major genetic subtypes (MYCN amplification or ATRX mutations) and those without such changes using single-cell transcriptomics and epigenomics. "Until now, only primary tumors have been studied in such detail, but not neuroblastoma metastases," says Irfete Fetahu, Ph.D., co-first author as well as co-corresponding author of the study and postdoc in the Tumor Biology Group.

The team examined the interaction of metastatic tumor cells with healthy bone marrow cells in more detail. "We developed algorithms that enabled us to analyze different cells in the bone marrow as well as to model their interactions," said Fortelny, head of the Computational Systems Biology Group, Paris Lodron University of Salzburg.

"Our analysis has shown that certain cells, so-called monocytes, react to unwanted invaders. In the course of this, they foster growth processes and release cytokines that stimulate ," explains Fetahu. Interestingly, investigations at the epigenetic level showed that although monocytes in the are activated to attack , they are unable to respond appropriately to these signals. "These monocytes receive contradictory messages. As a result, they are no longer able to fight the tumor," Fetahu said.

The communication between neuroblastoma cells and bone marrow or monocytes is to a large extent regulated by the proteins MK (midkine), MIF (macrophage migration inhibitory factor) and associated molecules. Signaling pathways controlled by these proteins are upregulated in immune cells. "Drugs targeting MK and MIF disrupt this pathological interaction and are currently under investigation. Through , it could be possible to return these pathologically altered monocytes to their original state," says Taschner-Mandl.

Metastases act differently

The scientists also found that cellular plasticity, i.e. the ability of cells to change depending on environmental influences, is retained during metastasis. In addition, the gene expression of metastatic tumor cells depends on the neuroblastoma genetic subtype. For example, neuroblastoma cells that have a MYCN amplification only slightly change when they metastasize from the to the bone marrow, whereas tumor cells with ATRX mutation show pronounced differences upon metastasis.

"The genetics of the tumor lead to characteristic signals and thus very specific changes in the microenvironment of the , which is expressed in individual signatures," says Taschner-Mandl. "This could explain why neuroblastoma patients with ATRX mutations often respond poorly to therapy."

More information: Single-cell transcriptomics and epigenomics unravel the role of monocytes in neuroblastoma bone marrow metastasis, Nature Communications (2023). DOI: 10.1038/s41467-023-39210-0

Journal information: Nature Communications
Provided by St. Anna Children's Cancer Research Institute
Citation: Childhood cancer: Vulnerability in the immune response against metastases discovered (2023, June 26) retrieved 20 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Natural 'brake' against malignant neuroblastoma turns tumors benign


Feedback to editors